Ear­ly-stage can­cer biotech nails $85M C round; Flem­ming Orn­skov's Gal­der­ma scores 'break­through' sta­tus

→ Zen­tal­is Phar­ma­ceu­ti­cals just nabbed an $85 mil­lion round from a syn­di­cate that in­cludes Ma­trix Cap­i­tal, Viking Glob­al In­vestors, Red­mile Group, Far­al­lon Cap­i­tal, Per­cep­tive Ad­vi­sors, Sur­vey­or Cap­i­tal and Even­tide As­set Man­age­ment. Their lead drug is ZN-c5, which is cur­rent­ly in Phase I/II tri­als. The biotech de­scribes that drug as a “po­ten­tial best-in-class oral Se­lec­tive Es­tro­gen Re­cep­tor De­grad­er for es­tro­gen re­cep­tor-pos­i­tive, HER2-neg­a­tive (ER+/ HER2-) breast can­cer.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER